URMC Research Network

Find People
Keyword
Last Name
 
More Search Options

John Frelinger

TitleProfessor
InstitutionSchool of Medicine and Dentistry
DepartmentMicrobiology and Immunology
AddressUniversity of Rochester Medical Center
School of Medicine and Dentistry
601 Elmwood Ave, Box 704
Rochester NY 14642
 
 Awards And Honors
      2014 Chair Education Committee (AAI)  | AAI
1971 - 1975National Merit Scholarship
1975     B.S. with Distinction and Departmental Honors
1981 - 1983Jane Coffin Childs Fellowship
1983 - 1984American Cancer Society Senior Fellowship, California Division
1986 - 1988Junior Faculty Research Award  | American Cancer Society
1991 - 1993Andrew W. Mellon Deans Teaching Scholar  | Excellence in Teaching and Research
1994     Special Commendation Teaching-Medical School
1995     Herbert W. Mapstone Prize for Teaching Excellence
1996     Special Commendation Teaching-Medical School
1998     Herbert W. Mapstone Prize for Teaching Excellence
2000     Faculty Speaker, Medical School Class of 2000 Awards Ceremony
2000     Distinguished Speaker
2002     Special Commendation Teaching-Medical School
2011 - 2014AAI Education Committee  | American Association of Immunologists
2012     Alumni Gold Medal Teaching Award
 
 Overview
My laboratory has a number of interests united by the common theme of T cell recognition. One focus of research has been the generation and maintenance of effective T cell responses to tumors. It has become apparent that anti-tumor responses can be directed against differentiation antigens. Thus, even with multiple mechanisms of establishing and maintaining tolerance, tolerance is not absolute. We hypothesize that it is possible to direct an effective response against tumors by inducing an autoimmune response to organ-specific antigens. To examine this hypothesis, we will use transgenic mice lines we have developed which specifically express human PSA in the prostate and investigate how this expression affects their ability to generate CTL responses to human PSA using novel immunization strategies. In this light, we have been working on developing novel viral vectors for immunization. Helper free herpes amplicons, plasmid based vectors that have an extremely large coding capacity, are attractive viral vaccine candidates for expressing recombinant proteins in vivo for immunization. The amplicon system has particular promise since it encodes no viral gene products and we have shown it very effectively infects dendritic cells. In collaboration with Edith Lord and in conjunction with Tom Foster's laboratory in the Department of Imaging Sciences, we have devised imaging approaches to look at the early steps in immunization and at the effector T cells generated. These studies will contribute to the rational design of immunotherapy for tumors as well as for HIV. We also believe that many of the techniques and approaches will be applicable to other infectious agents as well. In this regard, we are collaborating with investigators at University of North Carolina to identify T cell epitopes of Francisella tularensis. Francisella tularensis (FT) is a gram negative bacterium that is able to infect a wide range of mammalian hosts. FT has several properties that suggest could be developed as a biological weapon, including its ability to be aerosolized and its low LD50. Indeed, it has been asserted that FT was used as a bioweapon in World War II. Unfortunately relatively little information is available concerning the detailed cellular mechanism of resistance to re-infection either in humans or in experimental animals. However, as expected for a pathogen that grows largely intracellularly, T cells are believed to be a critical component in resistance to reinfection and recovery from primary infection. My laboratory has developed a technique called the TCAD ( the T-Cell antigen discovery technique) to identify and improve T cell epitopes, originally in the context of tumor vaccines. We have recently modified this system to large-scale screens for the identification of T cell epitopes from FT using this system which takes advantage of the tremendously enhanced efficiency particulate antigen cross-priming and a novel reporter system of T cell activation. It is hoped that the identification of the T cell epitopes recognized will yield to a batter understanding of the nature of a protective response and ultimately a defined vaccine.

 
 Selected Publications
List All   |   Timeline
  1. Skrombolas D, Frelinger JG. Challenges and developing solutions for increasing the benefits of IL-2 treatment in tumor therapy. Expert Rev Clin Immunol. 2014 Feb; 10(2):207-17.
    View in: PubMed
  2. Sedlacek AL, Gerber SA, Randall TD, van Rooijen N, Frelinger JG, Lord EM. Generation of a dual-functioning antitumor immune response in the peritoneal cavity. Am J Pathol. 2013 Oct; 183(4):1318-28.
    View in: PubMed
  3. Yokota SJ, Facciponte JG, Kelleher RJ, Shultz LD, Loyall JL, Parsons RR, Odunsi K, Frelinger JG, Lord EM, Gerber SA, Balu-Iyer SV, Bankert RB. Changes in ovarian tumor cell number, tumor vasculature, and T cell function monitored in vivo using a novel xenograft model. Cancer Immun. 2013; 13:11.
    View in: PubMed
  4. Gerber SA, Sedlacek AL, Cron KR, Murphy SP, Frelinger JG, Lord EM. IFN-? Mediates the Antitumor Effects of Radiation Therapy in a Murine Colon Tumor. Am J Pathol. 2013 Jun; 182(6):2345-54.
    View in: PubMed
  5. Gerber SA, Sorensen EW, Sedlacek AL, Lim JY, Skrombolas D, Frelinger JG, Lord EM. Local expression of interleukin-2 by B16 melanoma cells results in decreased tumour growth and long-term tumour dormancy. Immunology. 2013 Mar; 138(3):280-92.
    View in: PubMed
  6. Valentino MD, Abdul-Alim CS, Maben ZJ, Skrombolas D, Hensley LL, Kawula TH, Dziejman M, Lord EM, Frelinger JA, Frelinger JG. A broadly applicable approach to T cell epitope identification: application to improving tumor associated epitopes and identifying epitopes in complex pathogens. J Immunol Methods. 2011 Oct 28; 373(1-2):111-26.
    View in: PubMed
  7. Puskas J, Skrombolas D, Sedlacek A, Lord E, Sullivan M, Frelinger J. Development of an attenuated interleukin-2 fusion protein that can be activated by tumour-expressed proteases. Immunology. 2011 Jun; 133(2):206-20.
    View in: PubMed
  8. Valentino MD, Maben ZJ, Hensley LL, Woolard MD, Kawula TH, Frelinger JA, Frelinger JG. Identification of T-cell epitopes in Francisella tularensis using an ordered protein array of serological targets. Immunology. 2011 Mar; 132(3):348-60.
    View in: PubMed
  9. Sorensen EW, Gerber SA, Frelinger JG, Lord EM. IL-12 suppresses vascular endothelial growth factor receptor 3 expression on tumor vessels by two distinct IFN-gamma-dependent mechanisms. J Immunol. 2010 Feb 15; 184(4):1858-66.
    View in: PubMed
  10. Valentino MD, Hensley LL, Skrombolas D, McPherson PL, Woolard MD, Kawula TH, Frelinger JA, Frelinger JG. Identification of a dominant CD4 T cell epitope in the membrane lipoprotein Tul4 from Francisella tularensis LVS. Mol Immunol. 2009 May; 46(8-9):1830-8.
    View in: PubMed
  11. Valentino M, Frelinger J. An approach to the identification of T cell epitopes in the genomic era: application to Francisella tularensis. Immunol Res. 2009 Dec; 45(2-3):218-28.
    View in: PubMed
  12. Lugade AA, Sorensen EW, Gerber SA, Moran JP, Frelinger JG, Lord EM. Radiation-induced IFN-gamma production within the tumor microenvironment influences antitumor immunity. J Immunol. 2008 Mar 1; 180(5):3132-9.
    View in: PubMed
  13. Santos K, Simon DA, Conway E, Bowers WJ, Mitra S, Foster TH, Lugade A, Lord EM, Federoff HJ, Dewhurst S, Frelinger JG. Spatial and temporal expression of herpes simplex virus type 1 amplicon-encoded genes: implications for their use as immunization vectors. Hum Gene Ther. 2007 Feb; 18(2):93-105.
    View in: PubMed
  14. Ramanayake T, Simon DA, Frelinger JG, Lord EM, Robert J. In vivo study of T-cell responses to skin alloantigens in Xenopus using a novel whole-mount immunohistology method. Transplantation. 2007 Jan 27; 83(2):159-66.
    View in: PubMed
  15. Malboeuf CM, Simon DA, Lee YE, Lankes HA, Dewhurst S, Frelinger JG, Rose RC. Human papillomavirus-like particles mediate functional delivery of plasmid DNA to antigen presenting cells in vivo. Vaccine. 2007 Apr 30; 25(17):3270-6.
    View in: PubMed
  16. Mitra S, Cassar SE, Niles DJ, Puskas JA, Frelinger JG, Foster TH. Photodynamic therapy mediates the oxygen-independent activation of hypoxia-inducible factor 1alpha. Mol Cancer Ther. 2006 Dec; 5(12):3268-74.
    View in: PubMed
  17. Santos K, Duke CM, Rodriguez-Colon SM, Dakwar A, Fan S, Keefer MC, Federoff HJ, Frelinger JG, Bowers WJ, Dewhurst S. Effect of promoter strength on protein expression and immunogenicity of an HSV-1 amplicon vector encoding HIV-1 Gag. Vaccine. 2007 Feb 19; 25(9):1634-46.
    View in: PubMed
  18. Gerber SA, Rybalko VY, Bigelow CE, Lugade AA, Foster TH, Frelinger JG, Lord EM. Preferential attachment of peritoneal tumor metastases to omental immune aggregates and possible role of a unique vascular microenvironment in metastatic survival and growth. Am J Pathol. 2006 Nov; 169(5):1739-52.
    View in: PubMed
  19. Wagner VE, Frelinger JG, Barth RK, Iglewski BH. Quorum sensing: dynamic response of Pseudomonas aeruginosa to external signals. Trends Microbiol. 2006 Feb; 14(2):55-8.
    View in: PubMed
  20. Lugade AA, Moran JP, Gerber SA, Rose RC, Frelinger JG, Lord EM. Local radiation therapy of B16 melanoma tumors increases the generation of tumor antigen-specific effector cells that traffic to the tumor. J Immunol. 2005 Jun 15; 174(12):7516-23.
    View in: PubMed
  21. Gerber SA, Turner MJ, Lugade AA, Moran JP, Frelinger JG, Lord EM. Characterization of a lymph node within the mouse prostate: Detailed analysis using whole mount histology. Prostate. 2005 May 1; 63(2):105-16.
    View in: PubMed
  22. Bigelow CE, Vishwasrao HD, Frelinger JG, Foster TH. Imaging enzyme activity with polarization-sensitive confocal fluorescence microscopy. J Microsc. 2004 Jul; 215(Pt 1):24-33.
    View in: PubMed
  23. Mitra S, Goren EM, Frelinger JG, Foster TH. Activation of heat shock protein 70 promoter with meso-tetrahydroxyphenyl chlorin photodynamic therapy reported by green fluorescent protein in vitro and in vivo. Photochem Photobiol. 2003 Dec; 78(6):615-22.
    View in: PubMed
  24. Moran JP, Gerber SA, Martin CA, Frelinger JG, Lord EM. Transfection of the genes for interleukin-12 into the K1735 melanoma and the EMT6 mammary sarcoma murine cell lines reveals distinct mechanisms of antitumor activity. Int J Cancer. 2003 Sep 20; 106(5):690-8.
    View in: PubMed
  25. Gerber SA, Moran JP, Frelinger JG, Frelinger JA, Fenton BM, Lord EM. Mechanism of IL-12 mediated alterations in tumour blood vessel morphology: analysis using whole-tissue mounts. Br J Cancer. 2003 May 6; 88(9):1453-61.
    View in: PubMed
  26. Fisher TL, Nocera M, Willis RA, Turner MJ, Abdul Alim CS, Brown DM, Bourne PA, di Sant'Agnese PA, Messing EM, Lord EM, Frelinger JG. Generation of monoclonal antibodies specific for human kallikrein 2 (hK2) using hK2-expressing tumors. Prostate. 2002 May 15; 51(3):153-65.
    View in: PubMed
  27. Patel D, Frelinger J, Goudsmit J, Kim B. In vitro assay for site-specific proteases using bead-attached GFP substrate. Biotechniques. 2001 Nov; 31(5):1194, 1196, 1198 passim.
    View in: PubMed
  28. Willis RA, Bowers WJ, Turner MJ, Fisher TL, Abdul-Alim CS, Howard DF, Federoff HJ, Lord EM, Frelinger JG. Dendritic cells transduced with HSV-1 amplicons expressing prostate-specific antigen generate antitumor immunity in mice. Hum Gene Ther. 2001 Oct 10; 12(15):1867-79.
    View in: PubMed
  29. Turner MJ, Abdul-Alim CS, Willis RA, Fisher TL, Lord EM, Frelinger JG. T-cell antigen discovery (T-CAD) assay: a novel technique for identifying T cell epitopes. J Immunol Methods. 2001 Oct 1; 256(1-2):107-19.
    View in: PubMed
  30. Brown DM, Fisher TL, Wei C, Frelinger JG, Lord EM. Tumours can act as adjuvants for humoral immunity. Immunology. 2001 Apr; 102(4):486-97.
    View in: PubMed
  31. Greenwood R, Frelinger J. Mechanisms of unresponsiveness: T- and B-cell mediated mechanisms of anergy. Adv Exp Med Biol. 2001; 489:109-17.
    View in: PubMed
  32. Skrincosky D, Willis RA, Hocknell PK, Frelinger JG, Mirandola P, Wang X, Dewhurst S. Epitope mapping of human herpesvirus-7 gp65 using monoclonal antibodies. Arch Virol. 2001; 146(9):1705-22.
    View in: PubMed
  33. Wu YP, McMahon E, Kraine MR, Tisch R, Meyers A, Frelinger J, Matsushima GK, Suzuki K. Distribution and characterization of GFP(+) donor hematogenous cells in Twitcher mice after bone marrow transplantation. Am J Pathol. 2000 Jun; 156(6):1849-54.
    View in: PubMed
  34. Egan RM, Yorkey C, Black R, Loh WK, Stevens JL, Storozynsky E, Lord EM, Frelinger JG, Woodward JG. In vivo behavior of peptide-specific T cells during mucosal tolerance induction: antigen introduced through the mucosa of the conjunctiva elicits prolonged antigen-specific T cell priming followed by anergy. J Immunol. 2000 May 1; 164(9):4543-50.
    View in: PubMed
  35. Lee J, Moran JP, Fenton BM, Koch CJ, Frelinger JG, Keng PC, Lord EM. Alteration of tumour response to radiation by interleukin-2 gene transfer. Br J Cancer. 2000 Feb; 82(4):937-44.
    View in: PubMed
  36. Conway TF, Sabel MS, Sugano M, Frelinger JG, Egilmez NK, Chen F, Bankert RB. Growth of human tumor xenografts in SCID mice quantified using an immunoassay for tumor marker protein in serum. J Immunol Methods. 2000 Jan 13; 233(1-2):57-65.
    View in: PubMed
  37. Martin BK, Frelinger JG, Ting JP. Combination gene therapy with CD86 and the MHC class II transactivator in the control of lung tumor growth. J Immunol. 1999 Jun 1; 162(11):6663-70.
    View in: PubMed
  38. Storozynsky E, Woodward JG, Frelinger JG, Lord EM. Interleukin-3 and granulocyte-macrophage colony-stimulating factor enhance the generation and function of dendritic cells. Immunology. 1999 May; 97(1):138-49.
    View in: PubMed
  39. Ostberg JR, Barth RK, Frelinger JG. The Roman god Janus: a paradigm for the function of CD43. Immunol Today. 1998 Dec; 19(12):546-50.
    View in: PubMed
  40. Hunt JP, Hunter CT, Brownstein MR, Giannopoulos A, Hultman CS, deSerres S, Bracey L, Frelinger J, Meyer AA. The effector component of the cytotoxic T-lymphocyte response has a biphasic pattern after burn injury. J Surg Res. 1998 Dec; 80(2):243-51.
    View in: PubMed
  41. Wei C, Callahan BP, Turner MJ, Willis RA, Lord EM, Barth RK, Frelinger JG. Regulation of human prostate-specific antigen gene expression in transgenic mice: evidence for an enhancer between the PSA and human glandular kallikrein-1 genes. Int J Mol Med. 1998 Oct; 2(4):487-96.
    View in: PubMed
  42. Yeh KY, McAdam AJ, Pulaski BA, Shastri N, Frelinger JG, Lord EM. IL-3 enhances both presentation of exogenous particulate antigen in association with class I major histocompatibility antigen and generation of primary tumor-specific cytolytic T lymphocytes. J Immunol. 1998 Jun 15; 160(12):5773-80.
    View in: PubMed
  43. Lord EM, Yeh KY, Moran JA, Storozynsky E, Frelinger JG. IL-3-mediated enhancement of particulate antigen presentation by macrophages. J Immunother. 1998 May; 21(3):205-10.
    View in: PubMed
  44. Lord EM, Frelinger JG. Tumor immunotherapy: cytokines and antigen presentation. Cancer Immunol Immunother. 1998 Apr; 46(2):75-81.
    View in: PubMed
  45. Hunt JP, Hunter CT, Brownstein M, Hultman CS, deSerres S, Bracey L, Frelinger J, Meyer AA. Host priming, not target antigen type, decides rejection rate in mice primed with MHC II "knockout" cultured keratinocytes. J Surg Res. 1998 Apr; 76(1):32-6.
    View in: PubMed
  46. Lee J, Fenton BM, Koch CJ, Frelinger JG, Lord EM. Interleukin 2 expression by tumor cells alters both the immune response and the tumor microenvironment. Cancer Res. 1998 Apr 1; 58(7):1478-85.
    View in: PubMed
  47. Willis RA, Wei C, Turner MJ, Callahan BP, Pugh AE, Barth RK, Lord EM, Frelinger JG. A transgenic strategy for analyzing the regulatory regions of the human prostate-specific antigen gene: potential applications for the treatment of prostate cancer (Review). Int J Mol Med. 1998 Feb; 1(2):379-86.
    View in: PubMed
  48. Ostberg JR, Dragone LL, Borrello MA, Phipps RP, Barth RK, Frelinger JG. Expression of mouse CD43 in the B cell lineage of transgenic mice causes impaired immune responses to T-independent antigens. Eur J Immunol. 1997 Sep; 27(9):2152-9.
    View in: PubMed
  49. Wei C, Willis RA, Tilton BR, Looney RJ, Lord EM, Barth RK, Frelinger JG. Tissue-specific expression of the human prostate-specific antigen gene in transgenic mice: implications for tolerance and immunotherapy. Proc Natl Acad Sci U S A. 1997 Jun 10; 94(12):6369-74.
    View in: PubMed
  50. McEvoy LM, Sun H, Frelinger JG, Butcher EC. Anti-CD43 inhibition of T cell homing. J Exp Med. 1997 Apr 21; 185(8):1493-8.
    View in: PubMed
  51. Ostberg JR, Dragone LL, Driskell T, Moynihan JA, Phipps R, Barth RK, Frelinger JG. Disregulated expression of CD43 (leukosialin, sialophorin) in the B cell lineage leads to immunodeficiency. J Immunol. 1996 Dec 1; 157(11):4876-84.
    View in: PubMed
  52. Wei C, Storozynsky E, McAdam AJ, Yeh KY, Tilton BR, Willis RA, Barth RK, Looney RJ, Lord EM, Frelinger JG. Expression of human prostate-specific antigen (PSA) in a mouse tumor cell line reduces tumorigenicity and elicits PSA-specific cytotoxic T lymphocytes. Cancer Immunol Immunother. 1996 Jul; 42(6):362-8.
    View in: PubMed
  53. Pulaski BA, Yeh KY, Shastri N, Maltby KM, Penney DP, Lord EM, Frelinger JG. Interleukin 3 enhances cytotoxic T lymphocyte development and class I major histocompatibility complex "re-presentation" of exogenous antigen by tumor-infiltrating antigen-presenting cells. Proc Natl Acad Sci U S A. 1996 Apr 16; 93(8):3669-74.
    View in: PubMed
  54. McAdam AJ, Pulaski BA, Storozynsky E, Yeh KY, Sickel JZ, Frelinger JG, Lord EM. Analysis of the effect of cytokines (interleukins 2, 3, 4, and 6, granulocyte-monocyte colony-stimulating factor, and interferon-gamma) on generation of primary cytotoxic T lymphocytes against a weakly immunogenic tumor. Cell Immunol. 1995 Oct 15; 165(2):183-92.
    View in: PubMed
  55. Yeh KY, Pulaski BA, Woods ML, McAdam AJ, Gaspari AA, Frelinger JG, Lord EM. B7-1 enhances natural killer cell-mediated cytotoxicity and inhibits tumor growth of a poorly immunogenic murine carcinoma. Cell Immunol. 1995 Oct 15; 165(2):217-24.
    View in: PubMed
  56. McAdam AJ, Pulaski BA, Harkins SS, Hutter EK, Lord EM, Frelinger JG. Synergistic effects of co-expression of the TH1 cytokines IL-2 and IFN-gamma on generation of murine tumor-reactive cytotoxic cells. Int J Cancer. 1995 May 29; 61(5):628-34.
    View in: PubMed
  57. Dragone LL, Barth RK, Sitar KL, Disbrow GL, Frelinger JG. Disregulation of leukosialin (CD43, Ly48, sialophorin) expression in the B-cell lineage of transgenic mice increases splenic B-cell number and survival. Proc Natl Acad Sci U S A. 1995 Jan 17; 92(2):626-30.
    View in: PubMed
  58. McAdam AJ, Felcher A, Woods ML, Pulaski BA, Hutter EK, Frelinger JG, Lord EM. Transfection of transforming growth factor-beta producing tumor EMT6 with interleukin-2 elicits tumor rejection and tumor reactive cytotoxic T-lymphocytes. J Immunother Emphasis Tumor Immunol. 1994 Apr; 15(3):155-64.
    View in: PubMed
  59. Woods ML, McAdam AJ, Frelinger JG, Lord EM. Isolation and expansion of tumor-infiltrating lymphocytes. Biotechniques. 1993 Dec; 15(6):970-2.
    View in: PubMed
  60. McAdam AJ, Yeh KY, Pulaski BA, Frelinger JG, Lord EM. Interleukin-3 inhibits the generation of nonspecific killers by interleukin-2. J Immunother Emphasis Tumor Immunol. 1993 Nov; 14(4):293-7.
    View in: PubMed
  61. Lord E, McAdam A, Felcher A, Woods M, Pulaski B, Hutter E, Frelinger J. Transfection of TGF-beta producing tumors with IL-2 elicits tumor rejection. Ann N Y Acad Sci. 1993 Aug 12; 690:346-8.
    View in: PubMed
  62. McAdam A, Pulaski B, Harkins S, Hutter E, Frelinger J, Lord E. Coexpression of IL-2 and gamma-IFN enhances tumor immunity. Ann N Y Acad Sci. 1993 Aug 12; 690:349-51.
    View in: PubMed
  63. Pulaski BA, McAdam AJ, Hutter EK, Biggar S, Lord EM, Frelinger JG. Interleukin 3 enhances development of tumor-reactive cytotoxic cells by a CD4-dependent mechanism. Cancer Res. 1993 May 1; 53(9):2112-7.
    View in: PubMed
  64. Gaspari AA, Ferbel B, Frelinger JG. Thy 1+ dendritic epidermal cells but not Langerhans cells express Ly 48. J Invest Dermatol. 1993 Mar; 100(3):247-53.
    View in: PubMed
  65. Baecher-Allan CM, Kemp JD, Dorfman KS, Barth RK, Frelinger JG. Differential epitope expression of Ly-48 (mouse leukosialin). Immunogenetics. 1993; 37(3):183-92.
    View in: PubMed
  66. McAdam AJ, Blieden TM, Frelinger JG, Lord EM. CD4-class II major histocompatibility complex interaction does not enhance killing by a class I-restricted CD4+CD8+ cytotoxic T cell clone. Eur J Immunol. 1992 Sep; 22(9):2461-4.
    View in: PubMed
  67. Cerosaletti KM, Woodward JG, Lord EM, Frelinger JG. Two regions of the H-2 Dd promoter are responsive to dimethylsulfoxide in line 1 cells by a mechanism distinct from IFN-gamma. J Immunol. 1992 Feb 15; 148(4):1212-21.
    View in: PubMed
  68. Dragone L, Pallant A, Insel R, Frelinger JG. CD43 is expressed normally on Wiskott-Aldrich-derived lymphocytes. Exp Clin Immunogenet. 1992; 9(3):130-40.
    View in: PubMed
  69. Blieden TM, McAdam AJ, Frelinger JG, Lord EM. Mechanism of cytolytic T lymphocyte killing of a low class I-expressing tumor. J Immunol. 1991 Aug 15; 147(4):1433-8.
    View in: PubMed
  70. Lombardi G, Matsui M, Moots R, Aichinger G, Sidhu S, Batchelor R, McMichael AJ, Frelinger J, Lechler R. Structural relationship between HLA-A2-restricted and anti-A2 allospecific T-cell recognition: analysis by mutation of the codons for polymorphic and conserved residues. Transplant Proc. 1991 Feb; 23(1 Pt 1):446-8.
    View in: PubMed
  71. Lombardi G, Matsui M, Moots R, Aichinger G, Sidhu S, Batchelor R, Frelinger J, Lechler R. Limited regions of the alpha 2-domain alpha-helix control anti-A2 allorecognition: an analysis using a panel of A2 mutants. Immunogenetics. 1991; 34(3):149-56.
    View in: PubMed
  72. Blieden TM, McAdam AJ, Foresman MD, Cerosaletti KM, Frelinger JG, Lord EM. Class-I MHC expression in the mouse lung carcinoma, line 1: a model for class-I inducible tumors. Int J Cancer Suppl. 1991; 6:82-9.
    View in: PubMed
  73. Dorfman KS, Litaker W, Baecher CM, Frelinger JG. The nucleotide sequence of Ly 48 (mouse leukosialin, sialophorin): the mouse homolog of CD43. Nucleic Acids Res. 1990 Aug 25; 18(16):4932.
    View in: PubMed
  74. Phipps RP, Baecher C, Frelinger JG, Penney DP, Keng P, Brown D. Differential expression of interleukin 1 alpha by Thy-1+ and Thy-1- lung fibroblast subpopulations: enhancement of interleukin 1 alpha production by tumor necrosis factor-alpha. Eur J Immunol. 1990 Aug; 20(8):1723-7.
    View in: PubMed
  75. Pallant A, Fukuda M, Frelinger JG. CD43 (leukosialin, sialophorin, large sialoglycoprotein) can be expressed in both normal and Wiskott-Aldrich fibroblasts via transfection of a leukosialin cDNA. Eur J Immunol. 1990 Jul; 20(7):1423-8.
    View in: PubMed
  76. Cerosaletti KM, Blieden TM, Harwell LW, Welsh KM, Frelinger JG, Lord EM. Alteration of the metastatic potential of line 1 lung carcinoma cells: opposite effects of class I antigen induction by interferons versus DMSO or gene transfection. Cell Immunol. 1990 May; 127(2):299-310.
    View in: PubMed
  77. Heath WR, Hurd ME, Murray R, Frelinger J, Sherman LA. Analysis of novel residues of class I involved in recognition by alloreactive T cells. Immunogenetics. 1990; 32(2):138-41.
    View in: PubMed
  78. Baecher CM, Dorfman KS, Mattei MG, Frelinger JG. cDNA cloning and localization of the mouse leukosialin gene (Ly48) to chromosome 7. Immunogenetics. 1990; 31(5-6):307-14.
    View in: PubMed
  79. Pallant A, Eskenazi A, Mattei MG, Fournier RE, Carlsson SR, Fukuda M, Frelinger JG. Characterization of cDNAs encoding human leukosialin and localization of the leukosialin gene to chromosome 16. Proc Natl Acad Sci U S A. 1989 Feb; 86(4):1328-32.
    View in: PubMed
  80. Bahler DW, Cerosaletti KM, Lord EM, Frelinger JG. Molecular analysis of deficient class I H-2 antigen expression by mouse lung carcinoma cells. J Immunol. 1988 Jun 1; 140(11):4003-12.
    View in: PubMed
  81. Dennert G, Landon C, Lord EM, Bahler DW, Frelinger JG. Lysis of a lung carcinoma by poly I:C-induced natural killer cells is independent of the expression of class I histocompatibility antigens. J Immunol. 1988 Apr 1; 140(7):2472-5.
    View in: PubMed
  82. Baecher CM, Infante AJ, Semcheski KL, Frelinger JG. Identification and characterization of a mouse cell surface antigen with alternative molecular forms. Immunogenetics. 1988; 28(5):295-302.
    View in: PubMed
  83. Bahler DW, Frelinger JG, Harwell LW, Lord EM. Reduced tumorigenicity of a spontaneous mouse lung carcinoma following H-2 gene transfection. Proc Natl Acad Sci U S A. 1987 Jul; 84(13):4562-6.
    View in: PubMed
  84. Sawicki JA, Frelinger JG, Palmer M, Buck DA, Dietzschold B, Wettstein PJ. Identical RT1 class II molecules are expressed by rat RT1m and RT1c haplotypes. J Immunol. 1985 Oct; 135(4):2853-8.
    View in: PubMed
  85. Frelinger JG, Shigeta M, Fathman CG. An analysis of monoclonal T cell and antibody recognition sites on Ia molecules. J Invest Dermatol. 1985 Jul; 85(1 Suppl):30s-33s.
    View in: PubMed
  86. Frelinger J, Sing A, Infante A, Fathman CG. Clonotypic antibodies which stimulate T cell clone proliferation. Immunol Rev. 1984 Oct; 81:21-38.
    View in: PubMed
  87. Frelinger JG, Shigeta M, Infante AJ, Nelson PA, Pierres M, Fathman CG. Multiple functional sites on a single Ia molecule defined using T cell clones and antibodies with chain-determined specificity. J Exp Med. 1984 Mar 1; 159(3):704-15.
    View in: PubMed
  88. Stroynowski I, Orn A, Goodenow RS, McMillan M, Forman J, Brayton PR, Frelinger J, Hood L. Cytotoxic T lymphocytes recognize determinants on the BALB/c-H-2Ld molecule controlled by alpha 1 and alpha 2 but not alpha 3 external domains. Immunogenetics. 1984; 20(2):141-54.
    View in: PubMed
  89. Fathman CG, Frelinger JG. T-lymphocyte clones. Annu Rev Immunol. 1983; 1:633-55.
    View in: PubMed
  90. Beck BN, Frelinger JG, Shigeta M, Infante AJ, Cummings D, Hämmerling G, Fathman CG. T cell clones specific for hybrid I-A molecules. Discrimination with monoclonal anti-I-Ak antibodies. J Exp Med. 1982 Oct 1; 156(4):1186-94.
    View in: PubMed
  91. Steinmetz M, Moore KW, Frelinger JG, Sher BT, Shen FW, Boyse EA, Hood L. A pseudogene homologous to mouse transplantation antigens: transplantation antigens are encoded by eight exons that correlate with protein domains. Cell. 1981 Sep; 25(3):683-92.
    View in: PubMed
  92. Frelinger JG, Hood L, Wettstein P. Analyses of RT1 products using two-dimensional polyacrylamide gels. Transplant Proc. 1981 Jun; 13(2):1360-3.
    View in: PubMed
  93. Wettstein PJ, Frelinger JG, Hood L. Serologic and biochemical analyses of rat class II molecules with anti-Ia sera. Transplant Proc. 1981 Jun; 13(2):1364-6.
    View in: PubMed
  94. Steinmetz M, Frelinger JG, Fisher D, Hunkapiller T, Pereira D, Weissman SM, Uehara H, Nathenson S, Hood L. Three cDNA clones encoding mouse transplantation antigens: homology to immunoglobulin genes. Cell. 1981 Apr; 24(1):125-34.
    View in: PubMed
  95. Frelinger JG, Frelinger JA, Hood L. Peptide map comparisons of epidermal and spleen H-2 molecules. Immunogenetics. 1981 Mar 1; 12(5-6):569-77.
    View in: PubMed
  96. Wettstein PJ, Frelinger JG, Hood L. Serological and biochemical characterization of rat (RT1) class II molecules with restricted mouse anti-Ia sera. Immunogenetics. 1981; 13(1-2):93-107.
    View in: PubMed
  97. Frelinger JA, Frelinger JG. Bone marrow origin of Ia molecules purified from epidermal cells. J Invest Dermatol. 1980 Jul; 75(1):68-70.
    View in: PubMed
  98. Blankenhorn EP, Cecka JM, Frelinger J, Götze D, Hood L. Structure of Ia antigens from the rat. Mouse alloantisera demonstrate at least two distinct molecular species. Eur J Immunol. 1980 Feb; 10(2):145-51.
    View in: PubMed
  99. Frelinger JG, Hood L, Hill S, Frelinger JA. Mouse epidermal Ia molecules have a bone marrow origin. Nature. 1979 Nov 15; 282(5736):321-3.
    View in: PubMed
  100. Frelinger JG, Motulsky H, Woodward DO. Effects of Chloramphenicol on the Circadian Rhythm of Neurospora crassa. Plant Physiol. 1976 Oct; 58(4):592-4.
    View in: PubMed

Visualizations


Frelinger's Networks

Concepts
_
Co-Authors
_
Similar People
_
Same Department